Perrigo Company today announced that it has agreed to settle
its Hatch-Waxman litigation relating to Minoxidil foam brought by Stiefel Research
Australia Pty. Ltd., a GSK Company. Under the terms of the settlement, Perrigo
can launch in the U. S.,
a generic version of Men’s Rogaine Foam on March 1, 2012, or earlier under
certain circumstances.
Rogaine@ (Minoxidil) Foam is used to regrow hair on the top
of the scalp, and has annual sales of approximately $60 million, as measured by
Information Resources, Inc. Perrigo’s Chairman and CEO Joseph C. Papa
concluded, “This is another example of Perrigo’s commitment to bring
products to market. Perrigo continues its focus on bringing quality, affordable
healthcare to consumers.”
